mab2617 antibody Search Results


dcir mab2617 ms novus biologicals if  (Novus Biologicals)
92
Novus Biologicals dcir mab2617 ms novus biologicals if
Dcir Mab2617 Ms Novus Biologicals If, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dcir mab2617 ms novus biologicals if/product/Novus Biologicals
Average 92 stars, based on 1 article reviews
dcir mab2617 ms novus biologicals if - by Bioz Stars, 2026-03
92/100 stars
  Buy from Supplier
dcir  (R&D Systems)
91
R&D Systems dcir
( A and B ) Representative immunofluorescence images of dorsal skin sections and fluorescence analysis of <t>DCIR</t> staining in the skin tissues of patients with AD and controls ( n = 8). Scale bar: 100 μm. ( C ) Quantification analysis of DCIR <t>+</t> <t>tryptase</t> + cells in the lesion skin of patients with AD and controls. ( D ) Flow cytometry analysis of DCIR expression in human mast cell line cKit + FcεRI + LAD2 cells. ( E ) Scheme of experimental protocol for the direct bindings of human recombinant DCIR (hrDCIR) to BSA, CRE, and Man-BSA. ( F ) Direct binding of different doses of hrDCIR (0–5.0 μg/mL) to BSA, CRE, or Man-BSA ( n = 3). ( G ) Representative immunofluorescence images of FITC-CRE uptake by LAD2. Scale bar: 15 μm. ( H and I ) Flow cytometry analysis ( H ) and quantification ( I ) of FITC-CRE uptake at different doses (1–500 ng/mL) by LAD2 cells ( n = 3). ( J ) Inhibition of FITC-CRE uptake in LAD2 cells pretreated with DCIR neutralizing antibody (α-DCIR) or IgG isotype ( n = 4). Data represent mean ± SEM of 2 independent experiments. Data in B , C , and I were compared using a 2-tailed Student’s t test. Data in F and J were compared by 2-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001.
Dcir, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dcir/product/R&D Systems
Average 91 stars, based on 1 article reviews
dcir - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
mab2617 antibody  (Merck KGaA)
90
Merck KGaA mab2617 antibody
( A and B ) Representative immunofluorescence images of dorsal skin sections and fluorescence analysis of <t>DCIR</t> staining in the skin tissues of patients with AD and controls ( n = 8). Scale bar: 100 μm. ( C ) Quantification analysis of DCIR <t>+</t> <t>tryptase</t> + cells in the lesion skin of patients with AD and controls. ( D ) Flow cytometry analysis of DCIR expression in human mast cell line cKit + FcεRI + LAD2 cells. ( E ) Scheme of experimental protocol for the direct bindings of human recombinant DCIR (hrDCIR) to BSA, CRE, and Man-BSA. ( F ) Direct binding of different doses of hrDCIR (0–5.0 μg/mL) to BSA, CRE, or Man-BSA ( n = 3). ( G ) Representative immunofluorescence images of FITC-CRE uptake by LAD2. Scale bar: 15 μm. ( H and I ) Flow cytometry analysis ( H ) and quantification ( I ) of FITC-CRE uptake at different doses (1–500 ng/mL) by LAD2 cells ( n = 3). ( J ) Inhibition of FITC-CRE uptake in LAD2 cells pretreated with DCIR neutralizing antibody (α-DCIR) or IgG isotype ( n = 4). Data represent mean ± SEM of 2 independent experiments. Data in B , C , and I were compared using a 2-tailed Student’s t test. Data in F and J were compared by 2-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001.
Mab2617 Antibody, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mab2617 antibody/product/Merck KGaA
Average 90 stars, based on 1 article reviews
mab2617 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


( A and B ) Representative immunofluorescence images of dorsal skin sections and fluorescence analysis of DCIR staining in the skin tissues of patients with AD and controls ( n = 8). Scale bar: 100 μm. ( C ) Quantification analysis of DCIR + tryptase + cells in the lesion skin of patients with AD and controls. ( D ) Flow cytometry analysis of DCIR expression in human mast cell line cKit + FcεRI + LAD2 cells. ( E ) Scheme of experimental protocol for the direct bindings of human recombinant DCIR (hrDCIR) to BSA, CRE, and Man-BSA. ( F ) Direct binding of different doses of hrDCIR (0–5.0 μg/mL) to BSA, CRE, or Man-BSA ( n = 3). ( G ) Representative immunofluorescence images of FITC-CRE uptake by LAD2. Scale bar: 15 μm. ( H and I ) Flow cytometry analysis ( H ) and quantification ( I ) of FITC-CRE uptake at different doses (1–500 ng/mL) by LAD2 cells ( n = 3). ( J ) Inhibition of FITC-CRE uptake in LAD2 cells pretreated with DCIR neutralizing antibody (α-DCIR) or IgG isotype ( n = 4). Data represent mean ± SEM of 2 independent experiments. Data in B , C , and I were compared using a 2-tailed Student’s t test. Data in F and J were compared by 2-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: JCI Insight

Article Title: Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKII-involved mast cell activation

doi: 10.1172/jci.insight.152559

Figure Lengend Snippet: ( A and B ) Representative immunofluorescence images of dorsal skin sections and fluorescence analysis of DCIR staining in the skin tissues of patients with AD and controls ( n = 8). Scale bar: 100 μm. ( C ) Quantification analysis of DCIR + tryptase + cells in the lesion skin of patients with AD and controls. ( D ) Flow cytometry analysis of DCIR expression in human mast cell line cKit + FcεRI + LAD2 cells. ( E ) Scheme of experimental protocol for the direct bindings of human recombinant DCIR (hrDCIR) to BSA, CRE, and Man-BSA. ( F ) Direct binding of different doses of hrDCIR (0–5.0 μg/mL) to BSA, CRE, or Man-BSA ( n = 3). ( G ) Representative immunofluorescence images of FITC-CRE uptake by LAD2. Scale bar: 15 μm. ( H and I ) Flow cytometry analysis ( H ) and quantification ( I ) of FITC-CRE uptake at different doses (1–500 ng/mL) by LAD2 cells ( n = 3). ( J ) Inhibition of FITC-CRE uptake in LAD2 cells pretreated with DCIR neutralizing antibody (α-DCIR) or IgG isotype ( n = 4). Data represent mean ± SEM of 2 independent experiments. Data in B , C , and I were compared using a 2-tailed Student’s t test. Data in F and J were compared by 2-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The sections were then incubated with the primary antibodies against mouse Tryptase (AF1937, R&D system), DCIR (MAB2617, R&D), or mouse IgG1 overnight at 4°C.

Techniques: Immunofluorescence, Fluorescence, Staining, Flow Cytometry, Expressing, Recombinant, Binding Assay, Inhibition

( A ) Representative skin images and EASI scores of PBS- and CRE-treated WT and DCIR –/– mice. ( B ) Representative H&E staining and epidermal thickness (μm) of skin tissues of PBS- and CRE-treated WT and DCIR –/– mice. ( C ) Representative Toluidine blue staining and quantification of cells with positive staining for Toluidine blue of skin tissue sections of PBS- and CRE-treated WT and DCIR –/– mice. Scale bar: 100 μm. Arrows represent mast cells. ( D ) Serum levels of specific IgE and IgG1 to CRE. ( E ) Quantitative PCR analysis of IL-4, IL-13, IL-33, and TNF-α expression in the skin tissues of PBS- and CRE-treated WT and DCIR –/– mice. Each circle represents 1 mouse. n = 8. Data represent mean ± SEM of 2 independent experiments. Data were compared by 2-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: JCI Insight

Article Title: Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKII-involved mast cell activation

doi: 10.1172/jci.insight.152559

Figure Lengend Snippet: ( A ) Representative skin images and EASI scores of PBS- and CRE-treated WT and DCIR –/– mice. ( B ) Representative H&E staining and epidermal thickness (μm) of skin tissues of PBS- and CRE-treated WT and DCIR –/– mice. ( C ) Representative Toluidine blue staining and quantification of cells with positive staining for Toluidine blue of skin tissue sections of PBS- and CRE-treated WT and DCIR –/– mice. Scale bar: 100 μm. Arrows represent mast cells. ( D ) Serum levels of specific IgE and IgG1 to CRE. ( E ) Quantitative PCR analysis of IL-4, IL-13, IL-33, and TNF-α expression in the skin tissues of PBS- and CRE-treated WT and DCIR –/– mice. Each circle represents 1 mouse. n = 8. Data represent mean ± SEM of 2 independent experiments. Data were compared by 2-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The sections were then incubated with the primary antibodies against mouse Tryptase (AF1937, R&D system), DCIR (MAB2617, R&D), or mouse IgG1 overnight at 4°C.

Techniques: Staining, Real-time Polymerase Chain Reaction, Expressing

( A ) Scheme of experimental protocol of i.v. transfer of DCIR + versus DCIR – mast cells into Kit W-sh/W-sh mice for the generation of AD mouse model. ( B ) Representative Toluidine blue staining and quantification of cells with positive staining for Toluidine blue of skin tissue sections of Kit W-sh/W-sh mice with DCIR + or DCIR – mast cells ( n = 9). ( C ) Representative immunofluorescence images of mast cells with (yellow) or without (blue) DCIR expression. ( D ) Representative skin images and EASI scores of Kit W-sh/W-sh mice with DCIR + or DCIR – mast cells ( n = 8). ( E ) Representative H&E staining and epidermal thickness (μm) of skin tissues of Kit W-sh/W-sh mice with DCIR + or DCIR – mast cells ( n = 8). Scale bar: 100 μm. Arrows represent mast cells. ( F ) Serum levels of specific IgE and IgG1 to CRE ( n = 8). ( G ) Quantitative PCR analysis of IL-4, IL-13, IL-33, and TNF-α expression in the skin tissues of Kit W-sh/W-sh mice with DCIR + or DCIR – mast cells. Each circle represents 1 mouse ( n = 8). Data represent mean ± SEM of 2 independent experiments. Data were compared by 2-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001.

Journal: JCI Insight

Article Title: Dendritic cell immunoreceptor drives atopic dermatitis by modulating oxidized CaMKII-involved mast cell activation

doi: 10.1172/jci.insight.152559

Figure Lengend Snippet: ( A ) Scheme of experimental protocol of i.v. transfer of DCIR + versus DCIR – mast cells into Kit W-sh/W-sh mice for the generation of AD mouse model. ( B ) Representative Toluidine blue staining and quantification of cells with positive staining for Toluidine blue of skin tissue sections of Kit W-sh/W-sh mice with DCIR + or DCIR – mast cells ( n = 9). ( C ) Representative immunofluorescence images of mast cells with (yellow) or without (blue) DCIR expression. ( D ) Representative skin images and EASI scores of Kit W-sh/W-sh mice with DCIR + or DCIR – mast cells ( n = 8). ( E ) Representative H&E staining and epidermal thickness (μm) of skin tissues of Kit W-sh/W-sh mice with DCIR + or DCIR – mast cells ( n = 8). Scale bar: 100 μm. Arrows represent mast cells. ( F ) Serum levels of specific IgE and IgG1 to CRE ( n = 8). ( G ) Quantitative PCR analysis of IL-4, IL-13, IL-33, and TNF-α expression in the skin tissues of Kit W-sh/W-sh mice with DCIR + or DCIR – mast cells. Each circle represents 1 mouse ( n = 8). Data represent mean ± SEM of 2 independent experiments. Data were compared by 2-way ANOVA. * P < 0.05, ** P < 0.01, *** P < 0.001.

Article Snippet: The sections were then incubated with the primary antibodies against mouse Tryptase (AF1937, R&D system), DCIR (MAB2617, R&D), or mouse IgG1 overnight at 4°C.

Techniques: Staining, Immunofluorescence, Expressing, Real-time Polymerase Chain Reaction